Jeannie Chern, MD, a gynecologic oncologist at Moffitt Cancer Center, discusses challenges with germline molecular testing for patients with ovarian cancer.

The cost associated with germline testing can be prohibitive for patients with ovarian cancer who are undergoing chemotherapy treatment, says Chern. However, some pharmaceutical companies may offer financial assistance so patients can be tested, explains Chern.

A lack of genetic counselors is also a rate-limiting challenge in this space, says Chern. Patients who undergo germline testing should have access to genetic counselors to help them understand whether they harbor an actionable target. Genetic counselors can also offer support and additional resources to a patient who may have a germline mutation, concludes Chern.

Videos

Jeannie Chern, MD, discusses challenges with germline molecular testing for patients with ovarian cancer.

Dr. Chern on Challenges Regarding Germline Testing in Ovarian Cancer

Jeannie Chern, MD, a gynecologic oncologist at Moffitt Cancer Center, discusses important germline and somatic mutations to be aware of in ovarian cancer.

 mutations, says Chern. Moderate penetrance genes include 

. The relationship between other mismatch repair genes like the Lynch syndrome genes are also being investigated. The homologous recombination deficiency genes also play a role in the space and may have therapeutic implications, adds Chern.

The first preclinical data with PARP inhibitors emerged in 2005. Now, these agents are indicated for use in the recurrent and frontline maintenance settings. The identification of these gene mutations and their role in treatment has significantly prolonged patients’ progression-free survival. As the field understands these mechanisms better, the role of treatment will continue to evolve, concludes Chern.

Jeannie Chern, MD

Articles

Dr. Chern on Challenges Regarding Germline Testing in Ovarian Cancer

Dr. Chern on Important Germline and Somatic Mutations in Ovarian Cancer